Yvonne Greenstreet, MBChB, CEO of Alnylam, expressed gratitude to all contributors to the clinical trials and emphasized the company’s commitment to further innovation for ATTR amyloidosis patients.

The big AI providers like OpenAI, Anthropic ... at 13:00 Alnylam Presents New Data from the HELIOS-B Phase 3 Study of ...

Yvonne Greenstreet, MBChB, CEO of Alnylam, expressed gratitude to all contributors to the clinical trials and emphasized the company’s commitment to further innovation for ATTR amyloidosis patients ..

FloQast, an Accounting Transformation Platform created by accountants for accountants, today announced the launch of FloQasttm AI Agents, a groundbreaking, auditable AI capability that, for the first ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Investing.com -- Alnylam Pharmaceuticals (NASDAQ: NASDAQ: ALNY) stock climbed 5% as trading resumed on Friday morning, following the company’s announcement that the FDA has approved AMVUTTRA for ...

BridgeBio Pharma, Inc. announced that it will present cardiovascular outcomes data from its Phase 3 study of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at the ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 17% price increase over the past week, likely influenced by its recent announcements and market trends. The company's R&D progress showcase on February 25 ...

AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.

Tempus AI, Inc. (NASDAQ: TEM), a technology company ... This study looked at the challenges of diagnosing cardiac transthyretin amyloidosis (cardiac ATTR) and how natural language processing ...